CARCINOMA, HEPATOCELLULAR

This study tested whether adding the immunotherapy drug pembrolizumab to standard supportive care helps Asian patients with advanced liver cancer live longer. The trial enrolled 453 patients who had already received one prior treatment. Results showed that pembrolizumab extended …

This study tested whether a radioactive oil called Lipiocis, injected into the liver artery, could prevent liver cancer from coming back after surgery or other curative treatments. It involved 73 adults with cirrhosis and liver cancer. The goal was to see if Lipiocis reduces tumo…

This study tested different combinations of immunotherapy drugs given before surgery for liver cancer that can be removed. The goal was to see if these treatments could shrink or eliminate the tumor before the operation. 62 participants took part, and the study is now complete.

This study tested a combination of two drugs, atezolizumab and bevacizumab, in 152 people with advanced liver cancer that could not be removed by surgery and had not been treated with systemic therapy before. The main goal was to check safety, especially serious bleeding side eff…

This study tested a new drug called E7386 combined with the immunotherapy pembrolizumab (and sometimes lenvatinib) in 89 people with advanced melanoma, colorectal cancer, or liver cancer that had stopped responding to prior treatments. The goal was to check safety and find the ri…

This study tested whether adding a third drug (relatlimab) to a standard two-drug combination (nivolumab and bevacizumab) is safe and works better for people with advanced liver cancer who haven't had treatment before. 83 adults with confirmed advanced liver cancer participated. …

This study tested whether adding pembrolizumab (an immunotherapy) to lenvatinib (a targeted therapy) helps people with advanced liver cancer live longer or slow tumor growth compared to lenvatinib alone. About 794 adults with liver cancer that could not be treated with surgery or…

This study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer procedure called TACE helps people with liver cancer that cannot be cured. About 479 adults with liver cancer that had not spread outside the liver took part. The goal was to see …

This study tested a new method called the mass response biomarker to see if it can predict how well a cancer patient will respond to specific treatments. Researchers collected tumor cells from 72 adults with various cancers using fluid samples or tissue biopsies. The goal was to …

This study looked at how common hepatitis B and C are in African and Asian immigrants living in Minnesota, and how these infections might lead to liver cancer. Researchers tested 892 adults for hepatitis markers and tracked liver cancer cases over time. The goal was to better und…